Compare · BLCO vs COO
BLCO vs COO
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and The Cooper Companies Inc. (COO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and COO operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 3.5x BLCO ($5.51B).
- Over the past year, BLCO is up 29.4% and COO is down 7.8% - BLCO leads by 37.2 points.
- BLCO has been more active in the news (16 items in the past 4 weeks vs 6 for COO).
- COO has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Bausch + Lomb Corporation
- The Cooper Companies Inc.
- Price
- $15.48+0.72%
- $66.37-1.46%
- Market cap
- $5.51B
- $19.03B
- 1M return
- -3.25%
- +8.61%
- 1Y return
- +29.43%
- -7.77%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 16
- 6
- Recent ratings
- 18
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
Latest BLCO
- SEC Form SD filed by Bausch + Lomb Corporation
- Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
- Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)
- Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)
- Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)
- Director Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)
- Director Ling Karen was granted 15,842 shares, increasing direct ownership by 35% to 61,518 units (SEC Form 4)
- Director Kavanagh Sarah B was granted 15,842 shares, increasing direct ownership by 30% to 69,541 units (SEC Form 4)
- Director Collis Steven H was granted 15,842 shares, increasing direct ownership by 61% to 42,003 units (SEC Form 4)
- Director Bernier Nathalie D. was granted 15,842 shares, increasing direct ownership by 23% to 85,505 units (SEC Form 4)
Latest COO
- SEC Form 10-Q filed by The Cooper Companies Inc.
- Needham reiterated coverage on Cooper with a new price target
- SEC Form 8-K filed by The Cooper Companies Inc.
- CooperCompanies Announces Second Quarter 2026 Results
- SEC Form SD filed by The Cooper Companies Inc.
- CooperVision Names Muru Annamalai as President, Asia-Pacific
- The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- CooperCompanies Appoints Paul Keel to its Board of Directors
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr